BALAJI AMINES LTD.-$

Balaji Amines Ltd has received a Warning cum Advisory Letter from the Securities and Exchange Board of India (SEBI) dated September 29th, 2026, received on September 30th, 2026. The letter addresses non-submission of disclosures related to a Directorate General of Foreign Trade (DGFT) order dated August 13, 2024, and a Food and Drug Administration (FDA) letter dated January 10, 2025. SEBI observed that the company failed to disclose the DGFT order placing it on the Denied Entity List and the FDA's warning regarding 'not of standard quality' Propylene Glycol. The company stated there is no material impact on its financials or operations. SEBI has warned the company to improve compliance standards and advised immediate disclosure of the aforementioned orders and explanations for the delay.

Balaji Amines Ltd has disclosed receipt of a Directions and Warning Letter dated January 10, 2025, from the Food & Drug Administration, Pune. The action stems from a customer's unauthorized resale of technical-grade Propylene Glycol for pharmaceutical use, contravening the Drugs and Cosmetics Act, 1940. The company states there is no material impact on its financials or operations. Balaji Amines has reviewed its sales practices, including clearer invoicing and end-use declarations, to prevent recurrence. The disclosure was made following a SEBI letter dated September 29, 2026, as the company initially believed the letter did not require immediate disclosure.

Balaji Amines Ltd has disclosed an order dated August 13, 2024, from the Director General of Foreign Trade (DGFT) placing the company on the Denied Entity List. This action is due to a violation of Export Obligation. The company received the order on August 13, 2024, and has been assigned license number 3111001781. Balaji Amines states that there is no material impact on its financials, operations, or other activities. The delay in disclosure was attributed to the company's initial view that the letter did not fall under the ambit of SEBI's disclosure regulations. A SEBI letter dated September 29, 2026, prompted the current submission.

Balaji Amines Ltd announced that Mr. Rajendrakumar Mohanprasad Tapadiya has completed his tenure as an Independent Director of Balaji Speciality Chemicals Limited, a material subsidiary of the company. His second term officially concluded from the close of business hours on September 28, 2026. The Board and Management of Balaji Speciality Chemicals Limited expressed their appreciation for his contributions during his term. This disclosure is made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Balaji Amines Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the un-audited financial results for the quarter and half-year ended September 30, 2026. All designated persons and their immediate relatives are prohibited from trading in the company's shares during this period. The date for the board meeting to approve these financial results will be communicated separately.

Balaji Amines Ltd has announced the successful commissioning of its Acetonitrile (ACN) plant at Unit-III, Solapur, Maharashtra, with effect from September 24, 2026. The plant utilizes advanced technology and is part of the company's expansion and modernization program. This commissioning enhances the installed capacity of the Acetonitrile plant to 1,440 Tonnes Per Month (TPM). The product caters to both domestic and international markets, falling under the Speciality Chemicals category.

Balaji Amines Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27). Consolidated Revenue from Operations stood at ₹461 crore, up from ₹403 crore in Q4FY26. EBITDA was ₹121 crore, with a 26% margin, and Net Profit (PAT) was ₹78 crore, with a 17% margin. Diluted EPS for Q1FY27 was ₹23.13. The company maintained stable operational performance despite lower volumes compared to Q1FY26. Balaji Amines also highlighted the successful commissioning of its 100,000 TPA Dimethyl Ether (DME) plant and ongoing expansion projects for N-Methyl Morpholine (NMM), Acetonitrile (ACN), and Balaji Speciality Chemicals, all targeted for commissioning in FY27.

Balaji Amines Limited announced the outcome of its Board Meeting held on July 27, 2026. The board considered and approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. Limited review reports from the statutory auditors were also taken note of. The meeting commenced at 4:30 PM and concluded at 5:35 PM.

Balaji Amines Ltd announced its un-audited standalone financial results for the quarter ended June 30, 2026. The company reported a significant increase in profit after tax, reaching ₹7,214.24 Lakhs, an 81% rise compared to ₹3,979.96 Lakhs in the same quarter last year. Revenue from operations also saw a healthy growth of 32% year-on-year, from ₹31,937.88 Lakhs to ₹42,273.75 Lakhs. Earnings per share (EPS) for the quarter stood at ₹22.27, up from ₹12.28 in the prior year's corresponding quarter. The board also took note of the limited review reports from the statutory auditors.

Balaji Amines Ltd has announced that its Board of Directors will convene on July 27, 2026. The primary agenda for this meeting is to consider, approve, and take on record the Un-audited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. Following the declaration of these financial results, the trading window for designated persons and their immediate relatives will reopen 48 hours after the announcement, as per the company's code of conduct for insider trading and corporate disclosure practices.